First Horizon Advisors Inc. Acquires 355 Shares of Omnicell, Inc. (NASDAQ:OMCL)

First Horizon Advisors Inc. increased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 36.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,333 shares of the company’s stock after purchasing an additional 355 shares during the quarter. First Horizon Advisors Inc.’s holdings in Omnicell were worth $59,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the business. Redmond Asset Management LLC grew its stake in shares of Omnicell by 0.3% in the fourth quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock worth $5,396,000 after purchasing an additional 371 shares during the last quarter. Rice Hall James & Associates LLC boosted its position in Omnicell by 13.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 70,595 shares of the company’s stock valued at $3,143,000 after acquiring an additional 8,144 shares in the last quarter. CIBC Asset Management Inc bought a new stake in Omnicell during the 4th quarter valued at approximately $201,000. Principal Financial Group Inc. boosted its position in Omnicell by 4.0% during the 4th quarter. Principal Financial Group Inc. now owns 238,356 shares of the company’s stock valued at $10,612,000 after acquiring an additional 9,267 shares in the last quarter. Finally, New York State Teachers Retirement System boosted its position in Omnicell by 2.4% during the 4th quarter. New York State Teachers Retirement System now owns 61,974 shares of the company’s stock valued at $2,759,000 after acquiring an additional 1,432 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Craig Hallum lifted their price objective on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. lifted their price objective on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Barclays lifted their price objective on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Benchmark reaffirmed a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. Finally, StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Omnicell presently has an average rating of “Hold” and an average target price of $52.33.

Insider Activity at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.64% of the stock is currently owned by insiders.

Omnicell Price Performance

OMCL stock opened at $38.47 on Friday. The firm has a 50 day moving average price of $42.53 and a 200-day moving average price of $43.82. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of 142.49, a PEG ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Equities research analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.